HealthcareServices

Palmoplantar Pustulosis Market Size and Demand Forecast 2026–2030

February 27, 2026March 2, 2026 by Marketing Posting

Uncover key drivers, emerging technologies, and competitive movements shaping the palmoplantar pustulosis market from 2026–2035 with trusted insights from The Business Research Company

How is the Palmoplantar Pustulosis Market size predicted to change over the forecast window of 2026–2035?

The palmoplantar pustulosis market size has demonstrated strong expansion in recent years. It is anticipated to increase from $2.09 billion in 2025 to $2.26 billion in 2026, achieving a compound annual growth rate (CAGR) of 7.8%. The growth observed historically is attributable to a scarcity of treatment options for chronic skin conditions, a reliance on corticosteroids and topical agents, prolonged diagnosis of pustular psoriasis, inadequate patient awareness concerning disease management, and a healthcare delivery model focused on hospitals.

The market for palmoplantar pustulosis is anticipated to experience robust expansion in the coming years. This market is projected to reach $3.03 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 7.6%. This expansion throughout the forecast period stems from factors such as the development of new biologics and systemic treatments, a rise in the uptake of targeted immunomodulators, the proliferation of teledermatology and digital health solutions, wider acceptance of home-based phototherapy, and enhanced access through online and retail pharmacies. Key trends anticipated during this period involve a surge in the embrace of biologic therapies, greater utilization of targeted immunomodulators, the broadening of home-based phototherapy options, the incorporation of teledermatology for managing chronic skin conditions, and improved availability of treatments via online pharmacies.

Access Your Free Sample Report for In-Depth Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=22090&type=smp

Which Drivers Are Contributing To The Expansion Of The Palmoplantar Pustulosis Market?

The rising occurrence of skin conditions is anticipated to fuel the expansion of the palmoplantar pustulosis market in the foreseeable future. These disorders encompass ailments impacting the skin’s architecture, operational capabilities, or visual state. The growing prevalence of such skin issues stems from shifts in environmental factors, personal lifestyle choices, and inherent genetic predispositions. Specific environmental elements, including atmospheric contamination, severe climatic patterns, and contact with detrimental substances, can irritate the skin, precipitating conditions such as eczema or acne. Palmoplantar pustulosis itself is a persistent dermal ailment, notably impacting the skin of the palms and soles, manifesting as pustules, erythema, and desquamation, though it is treatable with diverse therapies aimed at enhancing skin well-being and mitigating distress. A relevant example is observed in December 2023, where data from the National Institutes of Health (NIH), a U.S.-based entity serving as the principal medical research agency of the U.S. government, indicated that atopic dermatitis had a global prevalence of 2.6%, impacting approximately 204 million individuals globally. Consequently, the escalating incidence of skin disorders acts as a key catalyst for market expansion in the palmoplantar pustulosis sector.

What Segment Classifications Make Up The Palmoplantar Pustulosis Market?

The palmoplantar pustulosis market covered in this report is segmented –

1) By Treatment Type: Topical Treatments, Systemic Treatments, Biologics, Phototherapy

2) By Distribution Channel: Online Pharmacies, Retail Pharmacies

3) By Application: Hospitals, Dermatology Clinics, Homecare Settings

Subsegments:

1) By Topical Treatments: Corticosteroids, Vitamin D Analogues, Calcineurin Inhibitors, Keratolytics

2) By Systemic Treatments: Retinoids, Immunosuppressants, Phosphodiesterase-4 (PDE4) Inhibitors, Corticosteroids

3) By Biologics: Tumor Necrosis Factor (TNF) Inhibitors, Interleukin-17 (IL-17) Inhibitors, Interleukin-23 (IL-23) Inhibitors, Interleukin-12/23 (IL-12/23) Inhibitors

4) By Phototherapy: Narrowband UVB Therapy (NB-UVB), Psoralen plus Ultraviolet A (PUVA) Therapy, Excimer Laser Therapy, Targeted Phototherapy

What Upcoming Trends Are Likely To Define The Future Path Of The Palmoplantar Pustulosis Market?

Companies operating in the palmoplantar pustulosis market are increasingly focusing on the development of novel treatments, such as monoclonal antibodies designed to target inflammatory pathways, to enhance patient outcomes. A monoclonal antibody (mAb) is an identical antibody type, generated from a single B cell clone, which targets a specific antigen for either therapeutic or diagnostic purposes. As an illustration, in August 2023, Kyowa Kirin Co., Ltd., a pharmaceutical company from Japan, secured a partial change approval for LUMICEF for palmoplantar pustulosis in Japan. LUMICEF is a targeted therapeutic agent that blocks IL-17, delivering rapid and sustained relief for inflammatory ailments like psoriasis and palmoplantar pustulosis. Its objective is to diminish inflammation and improve the quality of life for patients experiencing these chronic conditions.

Which Leading Companies Dominate The Palmoplantar Pustulosis Market Share?

Major companies operating in the palmoplantar pustulosis market are Pfizer Inc., AbbVie Inc., Sanofi S.A., Bristol-Myers Squibb Company, Novartis International AG, GlaxoSmithKline PLC (GSK), Amgen Inc., Chugai Pharmaceutical Co. Ltd., Janssen Pharmaceuticals Inc., Kyowa Kirin Co. Ltd., Almirall S.A., MorphoSys AG, MoonLake Immunotherapeutics AG, Aristea Therapeutics Inc., AnaptysBio Inc., Kamari Pharma Ltd., Johnson & Johnson, AstraZeneca, Eli Lilly and Company, Bayer AG, Merck & Co. Inc., UCB S.A., Boehringer Ingelheim International GmbH, Arcutis Biotherapeutics, Affibody AB, LEO Pharma A/S, Galderma, Incyte Corporation, Takeda Pharmaceutical Company Ltd., Roivant Sciences

Access The Complete Report For Deeper Market Insights:

https://www.thebusinessresearchcompany.com/report/palmoplantar-pustulosis-global-market-report

Which Global Regions Are Shaping The Competitive Landscape Of The Palmoplantar Pustulosis Market?

North America was the largest region in the palmoplantar pustulosis market in 2025. The regions covered in the palmoplantar pustulosis market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request Your Customized Palmoplantar Pustulosis Market Research Report for Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=22090&type=smp

Browse Through More Reports Similar to the Global Palmoplantar Pustulosis Market 2026, By The Business Research Company

Plantar Fasciitis Treatment Market Report 2026

https://www.thebusinessresearchcompany.com/report/plantar-fasciitis-treatment-global-market-report

Scleroderma Market Report 2026

https://www.thebusinessresearchcompany.com/report/scleroderma-global-market-report

Ankylosing Spondylitis Market Report 2026

https://www.thebusinessresearchcompany.com/report/ankylosing-spondylitis-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795